Evaluation of endocrine resistance using ESR1 genotyping of circulating tumor cells and plasma DNA.

ABSTRACT:

Purpose

Therapeutic efficacy of hormonal therapies to target estrogen receptor (ER)-positive breast cancer is limited by the acquisition of ligand-independent ESR1 mutations, which confer treatment resistance to aromatase inhibitors (AIs). Monitoring for the emergence of such mutations may enable individualized therapy. We thus assessed CTC- and ctDNA-based detection of ESR1 mutations with the aim of evaluating non-invasive approaches for the determination of endocrine resistance.

Patients and methods

In a prospective cohort of 55 women with hormone receptor-positive metastatic breast cancer, we isolated circulating tumor cells (CTCs) and developed a high-sensitivity method for the detection of ESR1 mutations in these CTCs. In patients with sufficient plasma for the simultan

SUBMITTER: Sundaresan TK 

PROVIDER: S-EPMC8667563 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature